Desk
Side-effect reviews, compounding rules and the unapproved market.
29 stories · latest 10 Nov 2026
The SAF desk files side-effect reviews, recalls, warning letters and agency notices, along with reporting on the unregulated market where untested peptides are sold online.
A signal under review is not a confirmed side effect, and the stories keep the two apart. Each one names the agency, journal or registry behind it and says what action, if any, followed. Readers with symptoms or questions about their own treatment should talk to a doctor or pharmacist; this desk reports, it does not advise.
Doctors quoted by Men's Health say people on GLP 1 drugs do not automatically need B12 supplements and tie any shortfall to eating less, not poor absorption. The report cites no data on how often deficiency occurs.
NEW YORK
A GP at an online clinic told Mirror readers how to come off weight loss jabs. A BMJ review finds regain of about 0.8 kg a month after semaglutide and tirzepatide, and no tested taper exists in the sources checked.
LONDON · Mirror report, 9 Nov 2026; BMJ systematic review and meta-analysis (doi 10.1136/bmj-2025-085304), 7 Jan 2026
A LiveNow Fox report on Yahoo Health says people on GLP 1 drugs can enjoy Thanksgiving by filling half the plate with vegetables. The advice comes from a dietitian, the American Diabetes Association and UC Davis, and cites no study of holiday eating on these drugs.
SAN JOSE, CA · LiveNow Fox report carried by Yahoo Health, 9 Nov 2026, citing The Associated Press, a UC Davis release and the American Diabetes Association website
A nurse practitioner's MassLive column says 3 in 10 of 1,000 peptide users went to an emergency room but names no survey. Its other warnings match what regulators have found.
WESTFIELD, MASS. · Westfield Health Bulletin opinion column by nurse practitioner Juanita Carnes, MassLive, 6 Nov 2026
Two Baker Donelson attorneys say doctors who prescribe or source unapproved peptides still face license, criminal, fraud and malpractice exposure, even after a federal policy paused FDA enforcement against pharmacies compounding six peptides.
WASHINGTON · Healio Orthopedics Today expert submission by Baker Donelson attorneys Gary W. Herschman and Mark Yacura, 6 Nov 2026
Case reports and patient accounts describe skin that burns at a light touch on semaglutide and tirzepatide. Trials count a broader symptom, dysesthesia, more often with experimental retatrutide, but no study shows cause or frequency.
BOSTON · Daily Mail Health report, 5 Nov 2026, citing 2025 case reports and Phase 3 trial data
Hair loss is the most common of three GLP 1 concerns raised in a Straight Arrow News report, with the Zepbound label tying it to weight loss. NAION vision loss looks rare and unproven as a drug effect, and nail data are early.
NEW BRUNSWICK, NJ · Straight Arrow News report, 5 Nov 2026; Zepbound prescribing information on DailyMed
Three GPs quoted by the Daily Mail told people on weight loss jabs not to change their dose for Christmas. The UK Mounjaro leaflet sets missed dose rules, and no study cited measures planned festive pauses.
LONDON · Daily Mail column by Louise Atkinson, 4 Nov 2026; UK Mounjaro patient leaflet (Eli Lilly), revised Aug 2026
A UK GP told people on Mounjaro and Wegovy to use sharps bins, not recycling, after the BBC reported needles reaching a Coventry sorting plant. No national figures on discarded needles have been published.
COVENTRY, ENGLAND · Coventry Telegraph report, 3 Nov 2026, citing a BBC report on Sherborne Recycling in Coventry
The FDA's category 2 list cites deaths in studies of GHRP 2 and ipamorelin, without proven cause. The entries date to 2023, and the same page flags thin safety data for BPC 157 and five peptides now covered by an HHS policy.
SILVER SPRING, MD · FDA web page on bulk drug substances in category 2 of the compounding interim policies, content current as of 22 Apr 2026
Men's Health reviewed the research behind 19 synthetic peptides. For the six now open to pharmacy compounding under an HHS policy, most support comes from animal or cell studies, and none is FDA approved.
WASHINGTON · Men's Health peptide guide, 29 Oct 2026; FDA Pharmacy Compounding Advisory Committee meeting page, 23 to 24 Jul 2026
Pharmacists say the HHS policy offers a safer route than the gray market for six unapproved peptides. Pharmacologists say none has passed FDA testing, and it is unclear how long the policy lasts or whether outsourcing facilities are covered.
WASHINGTON · Everyday Health report carried by Yahoo News, 29 Oct 2026, citing the HHS enforcement discretion policy on 503A peptide compounding dated 28 Oct 2026
A pharmacist and three physicians told Yahoo Health that people on GLP 1 drugs should rethink NSAIDs, sedating antihistamines and combination cold products. The FDA's Wegovy label ties most kidney injury reports to dehydration.
NEW YORK · Yahoo Health report, 30 Oct 2026; FDA Wegovy prescribing information, Aug 2025 revision
A 32 year old Australian woman told ABC News she developed acute liver failure days after injecting a vial labelled retatrutide, an experimental drug the FDA says has not been found safe and effective for any condition.
NEW YORK · New York Post report citing ABC News Australia, 30 Oct 2026; FDA statement on unapproved GLP-1 drugs, updated 1 Oct 2026
Physician Joseph Varon told The National News Desk that some patients have diarrhea years after stopping GLP 1 drugs. The report said causation was not shown, and the meaning of rodent thyroid tumor findings for people remains unknown.
UNITED STATES · The National News Desk interview with physician Joseph Varon, published by CBS12, 29 Oct 2026
UT Southwestern endocrinologist Jeffrey Zigman says the GLP 1 thyroid warning targets medullary thyroid carcinoma and MEN2, not common thyroid disease, and sets out how levothyroxine users can space doses around oral Wegovy and Foundayo.
DALLAS · UT Southwestern Medical Center expert article by endocrinologist Jeffrey Zigman, released via Newswise on 28 Oct 2026 and republished by News-Medical
An emergency physician told OMED that GLP 1 drugs drive most peptide visits but warned about melanotan and the BPC 157 and TB 500 stack. Some of his approval claims do not match current labels.
LAS VEGAS · OMED session by Kenneth L. Frye Jr., DO, Oct 22 to 25 2026, Las Vegas, as reported in a Healio interview, 28 Oct 2026
Vision loss suits against Eli Lilly and Novo Nordisk are pooled in a Philadelphia federal court. Europe calls NAION a very rare semaglutide side effect, but one large U.S. study found no clear rise in risk.
PHILADELPHIA · MedShadow report, 28 Oct 2026, with EMA PRAC statement of 6 Jun 2025 and JAMA journal studies
A News-Medical research review says GLP 1 drugs show early but inconsistent signals in binge eating disorder, while a 45 member World Psychiatry panel backs screening every patient for eating disorders before treatment.
PUNE, INDIA · News-Medical research review, 26 Oct 2026; World Psychiatry Delphi consensus, Oct 2026; Eating and Weight Disorders meta-analysis, 2025
University of Queensland researchers say people injecting online peptides rarely see themselves as drug injectors and miss basic safety advice. NSW Health has warned hospitals of rising presentations, and needle programs report demand far above their contracts.
BRISBANE · The Conversation commentary by Akrigg, Ferris, Cornell and Piatkowski (University of Queensland), 26 Oct 2026; NSW Health Safety Information 009/26, 15 Oct 2026
Researchers at the Center for Science in the Public Interest say an FDA advisory committee vote backing six unapproved peptides, including BPC 157, for pharmacy compounding could undercut drug approval and put patients at risk.
WASHINGTON · JAMA Viewpoint by Samantaroy, Xu and Lurie (Center for Science in the Public Interest), published online 26 Oct 2026, doi 10.1001/jama.2026.19125
A Translational Psychiatry study of 24,103 matched pairs found adults with obesity and major depression who started tirzepatide had a lower recorded risk of suicidal ideation than those on other obesity drugs. The authors say it is not proof of a protective effect.
TAINAN · Translational Psychiatry, Liu, Chu et al., published 25 Oct 2026, doi 10.1038/s41398-026-04518-0
An Icelandic pharmacy chain and a wholesaler report rising demand for insulin syringes, while customs tests found many seized peptide vials did not contain what their labels claimed. The health minister says no national data on peptide use exist.
REYKJAVIK · RÚV report, 24 Oct 2026, with Icelandic Customs seizure (2 Mar 2026) and laboratory results (23 Jul 2026)
Japan's health ministry recirculated its June notice on GLP 1 and GIP/GLP 1 drugs after reports of ketosis related reactions in people using them for cosmetic or slimming purposes. It said a causal link is unknown.
TOKYO · Ministry of Health, Labour and Welfare notice of 14 Oct 2026, posted by the PMDA, with the Japan Society for the Study of Obesity statement of 3 Oct 2026
The American College of Obstetricians and Gynecologists advised against GLP 1 drugs in pregnancy and against their use while breastfeeding preterm infants or newborns. It said safety data remain too limited to call the drugs safe.
WASHINGTON · ACOG Practice Advisory on GLP-1 receptor agonists in pregnancy and lactation, with ACOG press release, 23 Oct 2026
Apothecary Pharma of Cary, North Carolina, recalled 22 lots of injectable tirzepatide it could not show were sterile. The FDA rated the recall Class II.
CARY, N.C. · FDA Enforcement Report, recall D-0036-2027, published 14 Oct 2026
TikTok now shows no results for searches on several named peptides, The Verge confirmed, but the broad topic and published videos remain visible and the company has not explained the change.
NEW YORK · The Verge report by Richard Lawler, 20 Oct 2026; FDA compounding safety risks page
Europe's pharmacovigilance committee concluded that non-arteritic anterior ischemic optic neuropathy is a very rare side effect of semaglutide medicines.
AMSTERDAM · European Medicines Agency, PRAC meeting highlights
With the shortage resolved, pharmacies that had been making copies of semaglutide got a fixed window to wind down. Tirzepatide had gone through the same step about two months earlier.
SILVER SPRING, Md. · FDA drug shortage list and statement to compounders
